Affiliation:
1. School of Medicine, “Carol Davila” University of Medicine and Pharmacy, 4192910 Bucharest, Romania
2. Fundeni Clinical Institute, 4192910 Bucharest, Romania
Abstract
Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin’s Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome associated with BV therapy. We present the case of a 64-year-old female, diagnosed with relapsed Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), who, after receiving six cycles of BV, developed authentic severe autoimmune hemolytic anemia with strong positive direct anti-globulin (Coombs) test, simultaneously associated with severe immune thrombocytopenia. The patient was unresponsive to systemic corticotherapy, but fully recovered after a course of IV immunoglobulin.
Reference15 articles.
1. Autoimmune hemolytic anemias, Evans’ syndromes, and pure red cell aplasia in non-Hodgkin lymphomas;Hauswirth;Leuk. Lymphoma,2007
2. Evans syndrome: Clinical perspectives, biological insights and treatment modalities;Elva;J. Blood Med.,2018
3. Audia, S., Grienay, N., Mounier, M., Michel, M., and Bonnotte, B. (2020). Evans’ Syndrome: From Diagnosis to Treatment. J. Clin. Med., 9.
4. Experience with Evans syndrome in an academic referral center;Rev. Bras. Hematol. Hemoter.,2015
5. Evans syndrome: A study of six cases with review of literature;Jain;Hematology,2008
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antineoplastics;Reactions Weekly;2023-05-20